Phase II Trial Investigates Vitamin D's Impact on Menstrual Cycle Health
The inVitD Trial is pivotal as it explores the relationship between vitamin D and menstrual health, potentially reshaping guidelines for fertility treatments. Positive outcomes could lead to new product development and marketing strategies in women's health.
Phase II
Women's Health / Fertility
Status
Active
Sponsor
Fertility
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Strategic implication
The inVitD Trial is pivotal as it explores the relationship between vitamin D and menstrual health, potentially reshaping guidelines for fertility treatments. Positive outcomes could lead to new product development and marketing strategies in women's health.
Why it matters
The inVitD Trial is pivotal as it explores the relationship between vitamin D and menstrual health, potentially reshaping guidelines for fertility treatments. Positive outcomes could lead to new product development and marketing strategies in women's health.
What changed
Trial Update
Analysis
The inVitD Trial aims to assess the effects of vitamin D supplementation on menstrual cycle hormones in women aged 19-40.
The inVitD Trial is pivotal as it explores the relationship between vitamin D and menstrual health, potentially reshaping guidelines for fertility treatments. Positive outcomes could lead to new product development and marketing strategies in women's health.
Monitor recruitment progress and initial findings regarding hormone levels and menstrual cycle regularity.
Related companies & assets
Companies
Assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.